Uses of anti-insulin-like growth factor I receptor antibodies

Details for Australian Patent Application No. 2004212344 (hide)

Owner Pfizer Products Inc.

Inventors Cusmano, John Daniel; Bedian, Vahe; Wang, Huifen Faye; Page, Kelly Lynn; Gomez-Navarro, Jesus; Cohen, Bruce David; Obrocea, Mihail; Guyot, Deborah Jean

Agent Spruson & Ferguson

Pub. Number AU-B-2004212344

PCT Pub. Number WO2004/071529

Priority 60/447,353 13.02.03 US

Filing date 3 February 2004

Wipo publication date 26 August 2004

Acceptance publication date 7 May 2009

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 5/00 (2006.01) Drugs for disorders of the endocrine system

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

4 August 2005 PCT application entered the National Phase

  PCT publication WO2004/071529 Priority application(s): WO2004/071529

7 May 2009 Application Accepted

  Published as AU-B-2004212344

3 September 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004212345-Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity

2004212337-Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders